CN108366994B - 新型Jak1选择性抑制剂及其用途 - Google Patents

新型Jak1选择性抑制剂及其用途 Download PDF

Info

Publication number
CN108366994B
CN108366994B CN201780004442.5A CN201780004442A CN108366994B CN 108366994 B CN108366994 B CN 108366994B CN 201780004442 A CN201780004442 A CN 201780004442A CN 108366994 B CN108366994 B CN 108366994B
Authority
CN
China
Prior art keywords
compound
disease
equiv
imidazo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780004442.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108366994A (zh
Inventor
梁从新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Gao Ling Pharmaceutical Co ltd
Original Assignee
Hangzhou Gaoguang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Gaoguang Pharmaceutical Co ltd filed Critical Hangzhou Gaoguang Pharmaceutical Co ltd
Priority to CN202110514751.5A priority Critical patent/CN113214278B/zh
Publication of CN108366994A publication Critical patent/CN108366994A/zh
Application granted granted Critical
Publication of CN108366994B publication Critical patent/CN108366994B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201780004442.5A 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途 Active CN108366994B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110514751.5A CN113214278B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403660P 2016-10-03 2016-10-03
US62/403,660 2016-10-03
PCT/US2017/054668 WO2018067422A1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110514751.5A Division CN113214278B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途

Publications (2)

Publication Number Publication Date
CN108366994A CN108366994A (zh) 2018-08-03
CN108366994B true CN108366994B (zh) 2021-10-01

Family

ID=61831161

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780004442.5A Active CN108366994B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途
CN202110514751.5A Active CN113214278B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110514751.5A Active CN113214278B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途

Country Status (19)

Country Link
US (3) USRE50799E1 (enExample)
EP (1) EP3509591B1 (enExample)
JP (1) JP7089141B2 (enExample)
KR (1) KR102399848B1 (enExample)
CN (2) CN108366994B (enExample)
AU (3) AU2017339417C1 (enExample)
DK (1) DK3509591T3 (enExample)
EA (1) EA201990523A1 (enExample)
ES (1) ES2901216T3 (enExample)
HK (1) HK1253040A1 (enExample)
HR (1) HRP20211965T1 (enExample)
HU (1) HUE058120T2 (enExample)
IL (3) IL265358B (enExample)
MX (1) MX390005B (enExample)
NZ (1) NZ751284A (enExample)
PL (1) PL3509591T3 (enExample)
PT (1) PT3509591T (enExample)
RS (1) RS62695B1 (enExample)
WO (1) WO2018067422A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366994B (zh) 2016-10-03 2021-10-01 杭州高光制药有限公司 新型Jak1选择性抑制剂及其用途
AU2018208516B2 (en) 2017-01-11 2021-07-08 Aqilion Ab Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
IL282643B2 (en) 2018-10-31 2025-08-01 Incyte Corp A selective jak1 inhibitor for use in a method of treating hematological disease
IL285999B2 (en) * 2019-03-05 2026-01-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
KR102785014B1 (ko) * 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
KR20250140639A (ko) * 2019-06-06 2025-09-25 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 다형성 물질 및 염의 다형성 물질
US20230192617A1 (en) 2020-05-19 2023-06-22 Bayer Cropscience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
WO2021249995A1 (en) 2020-06-10 2021-12-16 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
US20240307396A1 (en) * 2021-06-07 2024-09-19 The Regents Of The University Of California Compositions and methods for treating celiac disease
JP2024543198A (ja) * 2021-09-13 2024-11-19 ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド 中枢神経障害を治療する方法
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
WO2025224600A1 (en) * 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection
WO2025248468A1 (en) 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)
WO2026002028A1 (zh) * 2024-06-26 2026-01-02 杭州多域生物技术有限公司 稠杂芳环类化合物、其药物组合物及其应用
WO2026032213A1 (zh) * 2024-08-08 2026-02-12 普罗思特(南京)生物科技有限公司 取代的三环衍生物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071031A1 (en) * 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983092A (en) 1975-01-20 1976-09-28 Ciba-Geigy Corporation Phenylindane diamine mixture and epoxy resin therewith
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
EP1720855A4 (en) 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
CN101282974A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的咪唑并吡啶衍生物
CN101238186B (zh) 2005-08-11 2012-10-24 3M创新有限公司 作为金属基底涂层的互穿聚合物网络及其制造方法
WO2007039146A1 (en) 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
US7879968B2 (en) 2006-10-17 2011-02-01 Taylor Made Golf Company, Inc. Polymer compositions and golf balls with reduced yellowing
US20100280151A1 (en) 2009-05-04 2010-11-04 Toray Industries, Inc. Toughened fiber reinforced polymer composite with core-shell particles
WO2011041399A2 (en) * 2009-09-29 2011-04-07 Tyrogenex, Inc. Pi3k (delta) selective inhibitors
WO2011138657A1 (en) 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
BR112013008240A2 (pt) * 2010-10-08 2017-12-12 Abbvie Inc compostos de furo [3-2-d] pirimidina
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
PH12013502670A1 (en) * 2011-08-12 2016-07-29 Nissan Chemical Ind Ltd Tricyclic heterocyclic compounds and jak inhibitors
TW201319063A (zh) 2011-10-04 2013-05-16 Yakult Honsha Kk 以四氫噻唑衍生物或其鹽為有效成分之醫藥品
CN103450125B (zh) 2013-07-18 2016-01-13 嘉兴中科化学有限公司 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法
CA2926361A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
JP2017514832A (ja) 2014-04-30 2017-06-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ１抑制剤を調製する方法及びその新しい形態
EP2940022B1 (en) 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN105418620B (zh) 2014-09-23 2018-05-04 天津药明康德新药开发有限公司 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法
WO2016100349A2 (en) 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN106432232A (zh) 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
CN108366994B (zh) * 2016-10-03 2021-10-01 杭州高光制药有限公司 新型Jak1选择性抑制剂及其用途
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
CN107216334A (zh) 2017-06-29 2017-09-29 上海吉尔多肽有限公司 一种6‑氯呋喃[3,2‑b]吡啶的合成方法
KR20250140639A (ko) 2019-06-06 2025-09-25 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 다형성 물질 및 염의 다형성 물질
KR102803409B1 (ko) 2019-06-06 2025-05-07 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로서의 2,4,6-삼치환된 피리미딘 화합물
KR102785014B1 (ko) 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
CN114213424B (zh) 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071031A1 (en) * 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors

Also Published As

Publication number Publication date
BR112019005969A2 (pt) 2019-06-18
IL291267B2 (en) 2023-05-01
HRP20211965T1 (hr) 2022-03-18
HUE058120T2 (hu) 2022-07-28
IL291265A (en) 2022-05-01
WO2018067422A1 (en) 2018-04-12
IL291265B2 (en) 2023-05-01
PL3509591T3 (pl) 2022-01-31
CN113214278A (zh) 2021-08-06
JP7089141B2 (ja) 2022-06-22
IL291267A (en) 2022-05-01
CN108366994A (zh) 2018-08-03
JP2019537559A (ja) 2019-12-26
USRE49834E1 (en) 2024-02-13
US10738060B2 (en) 2020-08-11
PT3509591T (pt) 2021-12-27
EP3509591B1 (en) 2021-11-17
AU2017339417B2 (en) 2021-11-18
AU2022201061B2 (en) 2023-03-16
KR102399848B1 (ko) 2022-05-19
HK1253040A1 (zh) 2019-06-06
US20190256523A1 (en) 2019-08-22
RS62695B1 (sr) 2022-01-31
CN113214278B (zh) 2022-10-28
IL291265B1 (en) 2023-01-01
EA201990523A1 (ru) 2019-10-31
AU2017339417A1 (en) 2019-03-28
AU2022201061A1 (en) 2022-03-10
EP3509591A4 (en) 2020-03-25
IL265358A (en) 2019-05-30
NZ751284A (en) 2022-09-30
AU2017339417C1 (en) 2022-06-02
DK3509591T3 (da) 2021-12-20
USRE50799E1 (en) 2026-02-17
AU2022201058B2 (en) 2023-03-16
IL265358B (en) 2022-04-01
AU2022201058A1 (en) 2022-03-10
ES2901216T3 (es) 2022-03-21
IL291267B1 (en) 2023-01-01
MX390005B (es) 2025-03-20
CA3039178A1 (en) 2018-04-12
MX2019003649A (es) 2019-08-14
EP3509591A1 (en) 2019-07-17
KR20190057069A (ko) 2019-05-27

Similar Documents

Publication Publication Date Title
CN108366994B (zh) 新型Jak1选择性抑制剂及其用途
JP5629324B2 (ja) ピロロ［２，３−ｄ］ピリミジン化合物
JP6389511B2 (ja) 癌を治療するための、ｎｉｋ阻害剤としての３−（２−アミノピリミジン−４−イル）−５−（３−ヒドロキシプロピニル）−１ｈ−ピロロ［２，３−ｃ］ピリジン誘導体
TWI406864B (zh) 化合物
TW202304880A (zh) Ｎ２－苯基嘧啶－２，４－二胺化合物及其製備方法及使用方法
AU2016301212A1 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
WO2019070167A1 (ru) Ингибиторы рецептора эпидермального фактора роста
WO2019057112A1 (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN113214230B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
HK40047523B (en) Novel jak1 selective inhibitors and uses thereof
HK40047523A (en) Novel jak1 selective inhibitors and uses thereof
CA3039178C (en) Novel jak1 selective inhibitors and uses thereof
HK40004735B (en) Novel jak1 selective inhibitors and uses thereof
BR112019005969B1 (pt) Inibidores seletivos de jak1 e usos dos mesmos
EA040948B1 (ru) Селективные ингибиторы jak1 и их применение
HK40079587B (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180808

Address after: 510663 room 205, B tower, poly Central Plaza, 105 Pao Yue Road, Whampoa District, Guangzhou, Guangdong.

Applicant after: Guangzhou Gao Ling Pharmaceutical Co.,Ltd.

Address before: American Florida

Applicant before: Liang Congxin

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1253040

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 301, 302, building 4, Hexiang science and technology center, Qiantang new area, Hangzhou, Zhejiang Province 310000

Applicant after: Hangzhou Gaoguang Pharmaceutical Co.,Ltd.

Address before: Room 1-901, Heda Yaogu center, 291 Fucheng Road, Xiasha street, Qiantang New District, Hangzhou, Zhejiang Province

Applicant before: Hangzhou Gaoling Pharmaceutical Co.,Ltd.

Address after: Room 1-901, Heda Yaogu center, 291 Fucheng Road, Xiasha street, Qiantang New District, Hangzhou, Zhejiang Province

Applicant after: Hangzhou Gaoling Pharmaceutical Co.,Ltd.

Address before: Room 205, B / F, poly Zhongke Plaza, No. 105, guanyue Road, Huangpu District, Guangzhou City, Guangdong Province 510663

Applicant before: Guangzhou Gao Ling Pharmaceutical Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1253040

Country of ref document: HK